(Q37910243)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21810032%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

review article

1 reference

title

Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21810032%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21810032%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Eugenio Barone

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21810032%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

Raffaella Siciliano

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21810032%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

David Allan Butterfield

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21810032%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Paolo Preziosi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21810032%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

language of work or name

English

0 references

publication date

2 August 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21810032%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

9 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21810032%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21810032%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21810032%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

1243-1261

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21810032%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Non-apolipoprotein E and apolipoprotein E genetics of sporadic Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Amyloid beta-peptide is produced by cultured cells during normal metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Production of the Alzheimer amyloid beta protein by normal proteolytic processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Genetic and molecular aspects of Alzheimer's disease shed light on new mechanisms of transcriptional regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Mechanism of cytotoxicity mediated by the C31 fragment of the amyloid precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Beta-amyloid monomers are neuroprotective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Are Abeta and its derivatives causative agents or innocent bystanders in AD?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Acyclovir or Aβ42 peptides attenuate HSV-1-induced miRNA-146a levels in human primary brain cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Mechanisms of AD neurodegeneration may be independent of Aβ and its derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Neuropathologic and neurochemical correlates of psychosis in primary dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

In vivo oxidative stress in brain of Alzheimer disease transgenic mice: Requirement for methionine 35 in amyloid beta-peptide of APP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Oxidative stress hypothesis in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Protein oxidation and lipid peroxidation in brain of subjects with Alzheimer's disease: insights into mechanism of neurodegeneration from redox proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Proteomic identification of nitrated brain proteins in early Alzheimer's disease inferior parietal lobule

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Redox proteomics identification of 4-hydroxynonenal-modified brain proteins in Alzheimer's disease: Role of lipid peroxidation in Alzheimer's disease pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Increased CSF F2-isoprostane concentration in probable AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Malondialdehyde, carbonyl proteins and albumin-disulphide as useful oxidative markers in mild cognitive impairment and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Oxidative stress in the progression of Alzheimer disease in the frontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Increased levels of DNA breaks in cerebral cortex of Alzheimer's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Increased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Ribosome dysfunction is an early event in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Quantitative assessment of DNA fragmentation and beta-amyloid deposition in insular cortex and midfrontal gyrus from patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Mitochondrial dysfunction, endoplasmic reticulum stress, and apoptosis in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Loss of phospholipid asymmetry and elevated brain apoptotic protein levels in subjects with amnestic mild cognitive impairment and Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Mitochondrial function and alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Increase in Mrp1 expression and 4-hydroxy-2-nonenal adduction in heart tissue of Adriamycin-treated C57BL/6 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Calcium - a life and death signal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

High- and low-calcium-dependent mechanisms of mitochondrial calcium signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Acetylcholinesterase inhibition in Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Memantine in the treatment of mild-to-moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Donepezil for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Roles of nicotinic receptors in acetylcholinesterase inhibitor-induced neuroprotection and nicotinic receptor up-regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Donepezil treatment of severe Alzheimer's disease in nursing home settings. A responder analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Donepezil preserves cognition and global function in patients with severe Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Drug profile: transdermal rivastigmine patch in the treatment of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patchversus capsule

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Memantine: a review of its use in moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Efficacy and tolerability of memantine in the treatment of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Mitochondria as a target for neurotoxins and neuroprotective agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

21 January 2018

Dimebon disappointment

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Ispronicline: a novel alpha4beta2 nicotinic acetylcholine receptor-selective agonist with cognition-enhancing and neuroprotective properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Pharmacokinetics and safety profile of ispronicline (TC-1734), a new brain nicotinic receptor partial agonist, in young healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Effect of R3487/MEM3454, a novel nicotinic alpha7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Glutamate-based antidepressants: 20 years on.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Multiple-dose plasma pharmacokinetic and safety study of LY450108 and LY451395 (AMPA receptor potentiators) and their concentration in cerebrospinal fluid in healthy human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

AMPA potentiator treatment of cognitive deficits in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Alzheimer's failure raises questions about disease-modifying strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

A single ascending dose study of bapineuzumab in patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Methylene blue reduces aβ levels and rescues early cognitive deficit by increasing proteasome activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

NAP mechanisms of neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

The neuroprotective peptide NAP inhibits the aggregation of the beta-amyloid peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Synthesis and biological evaluation of benzodioxanylpiperazine derivatives as potent serotonin 5-HT(1A) antagonists: the discovery of Lecozotan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

A positron emission tomography study to assess binding of lecozotan, a novel 5-hydroxytryptamine-1A silent antagonist, to brain 5-HT1A receptors in healthy young and elderly subjects, and in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Therapeutic potential of CERE-110 (AAV2-NGF): targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Effects of Cerebrolysin on neurogenesis in an APP transgenic model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Changes in cognition and amyloid-β processing with long term cholesterol reduction using atorvastatin in aged dogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Alzheimer's disease: strategies for disease modification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Pharmacological treatment in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

A Neuronal Microtubule-Interacting Agent, NAPVSIPQ, Reduces Tau Pathology and Enhances Cognitive Function in a Mouse Model of Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.601740

10.1517/13543784.2011.601740

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21810032%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference